Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-20-021905
Filing Date
2020-02-14
Accepted
2020-02-14 16:34:17
Documents
1
Group Members
PETER KOLCHINSKYRAJEEV SHAH

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G/A tm207741-12_sc13ga.htm SC 13G/A 59340
  Complete submission text file 0001104659-20-021905.txt   61026
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Subject) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-44055 | Film No.: 20620902
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116
Business Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116 617-778-2500
RA CAPITAL MANAGEMENT, L.P. (Filed by) CIK: 0001346824 (see all company filings)

EIN.: 830406777 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A